Avaliação económica de ticagrelor em prevenção secundária pós Síndroma Coronária Aguda

Translated title of the contribution: Economic evaluation of ticagrelor for secondary prevention following acute coronary syndromes

Miguel Gouveia, Margarida Borges, Rosário Trindade*, Klas Rikner

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review



Introduction and Objectives To estimate the cost-effectiveness and cost-utility of ticagrelor in the treatment of patients with acute coronary syndromes (unstable angina or myocardial infarction with or without ST-segment elevation), including patients treated medically and those undergoing percutaneous coronary intervention or coronary artery bypass grafting. Methods A short-term decision tree and a long-term Markov model were used to simulate the evolution of patients' life-cycles. Clinical effectiveness data were collected from the PLATO trial and resource use data were obtained from the Hospital de Santa Marta database, disease-related group legislation and the literature. Results Ticagrelor provides increases of 0.1276 life years and 0.1106 quality-adjusted life years (QALYs) per patient. From a societal perspective these clinical gains entail an increase in expenditure of €610. Thus the incremental cost per life year saved is €4780 and the incremental cost per QALY is €5517. Conclusions The simulation results show that ticagrelor reduces events compared to clopidogrel. The costs of ticagrelor are partially offset by lower costs arising from events prevented. The use of ticagrelor in clinical practice is therefore cost-effective compared to generic clopidogrel.
Translated title of the contributionEconomic evaluation of ticagrelor for secondary prevention following acute coronary syndromes
Original languagePortuguese
Pages (from-to)17-25
Number of pages9
JournalRevista Portuguesa de Cardiologia
Issue number1
Publication statusPublished - 1 Jan 2015


  • Ticagrelor
  • Clopidogrel
  • Cost-effectiveness
  • Cost-utility
  • Acute coronary syndromes
  • Percutaneous coronary intervention
  • Coronary artery bypass grafting
  • ST-elevation myocardial infarction
  • Non-ST-elevation myocardial infarction


Dive into the research topics of 'Economic evaluation of ticagrelor for secondary prevention following acute coronary syndromes'. Together they form a unique fingerprint.

Cite this